Dermal fibroblast activation

Dermal fibroblast activation describes the process by which resting dermal fibroblasts respond to tissue injury, inflammation, or altered mechanical or biochemical cues by transitioning into a proliferative, contractile, and secretory phenotype (termed myofibroblast in its mature form). Activated fibroblasts are central to wound closure, extracellular matrix (ECM) production, and remodeling. Dysregulated or persistent activation underlies pathological fibrosis and plays a role in diverse diseases including cancer (tumor stroma formation), psoriasis, and atopic dermatitis. Fibroblast activation is driven by cytokines (notably TGF-β), growth factors, and mechanical signals, acting via intracellular pathways including SMAD, RhoA, and MAPK. The process is typically monitored by upregulation of biomarkers such as α-SMA, collagen, and fibronectin. No single receptor or molecule defines “dermal fibroblast activation,” and thus this term is not itself a canonical therapeutic target. In summary, "dermal fibroblast activation" is a cell state or process, not a single molecular entity or receptor, and thus is not suitable for classification as a canonical drug target or as a precise structured database entry.

Other names

Dermal fibroblast-myofibroblast transitionFibroblast activationFibroblast-to-myofibroblast transition (FMT)

Modulation by cytokines/growth factors (e.g., TGF-β, FGF, PDGF); Signal transduction through SMAD, MAPK, and other pathways; Mechanotransduction through extracellular matrix interaction.